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WOMEN OF CHILDBEARING POTENTIAL
IN CLINICAL RESEARCH:
PERSPECTIVES ON NIH POLICY AND LIABILITY ISSUES
By Eugene G. Hayunga, Karen H. Rothenberg, and Vivian W. Pinn*
I.

• to strengthen and enhance research related to diseases, disorders, and conditions that affect women
and to ensure that research conducted and supported by NIH adequately addresses issues
regarding women's health;
• to ensure that women are appropriately represented in biomedical and behavioral research studies
supported by NIH; and
• to develop opportunities for recruitment, retention,
re-entry, and advancement of women in biomedical careers.

Introduction

For many years there has been a presumption that
women of childbearing age are to be automatically
excluded from clinical studies. This approach has led to
continued gaps in our scientific knowledge, as important
information about metabolic activity and drug interactions
in this group of subjects is not readily available. As a
result, there is the possibility that drugs may be marketed with undetected side effects, or that the benefit of
potential treatments may be delayed for women who may
not have access to novel interventions as early in the
research process as their male or infertile female counterparts.
In the past government regulations have emphasized
the ethical principles of beneficence and respect for persons in protecting subjects from risks and assuring their
right NOT to participate in research studies.1 This has not
changed. But we now also recognize the important ethical principle of justice with regard to who receives the
benefits of clinical research and in assuring an individual's right TO participate in research. As a result, investigators are now encouraged to use fertile women earlier
in clinical trials. Such a change in thinking represents a
major landmark.
The new NIH requirements to include women as
research subjects reflect the most recent changes in
accepted standards of practice. In this article, we
describe the experience of the National Institutes' of
Health (NIH) in developing and implementing its policy
regarding the representation of women as research subjects, address the relevance of this policy to women of
childbearing potential and pregnant women, and consider the liability implications of their inclusion in research
studies.

II.

Ill.

It is the policy of NIH that women and members of
minority groups and their subpopulations must be included in all NIH-supported biomedical and behavioral
research projects involving human subjects, unless a
clear and compelling rationale and justification establishes to the satisfaction of the relevant Institute/Center
Director that inclusion is inappropriate with respect to the
health of the subjects or the purpose of the research.2
This policy has evolved over the last decade. The
Public Health Service assessed the representation of
women in clinical trials in 1985,3 and NIH policy has
addressed the inclusion of women and minority subjects
in clinical research since 1986.4 The policy was strengthened in 1990 in response to weaknesses noted in the
General Acqounting Office (GAO) report of that year.s
The NIH Revitalization Act of 1993 (PL 103-43) gave
existing policy the force of laws and stipulated some additional requirements, including a proscription against considering costs when evaluating research plans.7 The legislation also delineated some general exceptions to policy. a
The revised policy applies to all research involving
human subjects.9 As described in the Guidelines, clinical
research is defined broadly because of the need to
obtain data about minorities and both genders early in
the research process when hypotheses are being formulated, baseline data are being collected, and various
measurement instruments and intervention strategies
are being developed. to Phase Ill clinical trials are to be
designed and carried out in a manner that will provide for
valid analysis of whether the variables being studied
affect women or members of minority groups differently
than other subjects in the trial.11 In all cases, the
research study designs are evaluated prospectively by
the NIH, as funding is contingent upon a satisfactory

Role of the NIH Office of Research on
Women's Health

The Office of Research on Women's Health (ORWH)
was established in September 1990 within the Office of
the Director, NIH. ORWH serves as a focal point for
women's health research at NIH in setting and monitoring policy, promoting and stimulating research, and
enhancing scientific career development. ORWH works
in partnership with the NIH research institutes, centers,
and divisions to ensure that women's health research
becomes an integral part of the scientific fabric at NIH
and throughout the scientific community. ORWH has a
threefold mandate:
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One of the first steps in implementing the revised
policy was to familiarize the staff of some 23 separate
NIH institutes, centers, and divisions with the new
requirements. This task was especially critical in light of
findings by the General Accounting Office (GAO) in 1990.
that the earlier policy had been inconsistently applied
and had not been well communicated or understood
within NIH or the research community.13 Thus, the
changes mandated by the Revitalization Act provided an
opportunity to reinforce the NIH commitment to inclusion
by issuing renewed policy guidance, first to NIH staff and
then to the entire scientific research community.1 4
The NIH "Guidelines on the Inclusion of Women and
Minorities as Subjects in Clinical Research" were published as a Notice in the Federal Register on March 28,
1994 (Guidelines). The Notice described revisions to policy made in response to the Revitalization Act and invited public comments during the first year of implementation.15 A variety of outreach activities were also initiated
to explain the revised policy and to correct common misunderstandings about its requirements. NIH staff gave
presentations on the Guidelines at numerous professional meetings and workshops, and NIH published a
"Questions and Answers" document to provide more
detailed policy guidance and address some of the more
commonly asked questions about implementation of the
Guidelines.16
The Guidelines emphasize that the policy is intended
to address gaps in scientific knowledge. A clinical study
without appropriate numbers of women or minority subjects may be scientifically flawed, as would one without
an appropriate control group or one with serious methodological weaknesses. Thus, inclusion should be considered an issue of scientific merit. For this reason, it is the
responsibility of peer reviewers to assess a project's
inclusion plan as part of their evaluation of the research
design. Under NIH review procedures, any application or
proposal that is deemed unacceptable with regard to
inclusion during initial review receives an administrative
bar-to-funding, as does one found to be unacceptable
with regard to the safeguarding of human subjects or the
use of vertebrate laboratory animals. When this happens,
the situation that caused the bar must be corrected
before an NIH research institute or center may lift the bar
and make an award.17

was charged with examining the ethical and legal implications of policies that would broaden inclusion of
women in clinical trials, including women of childbearing
potential and pregnant women. 1B The Committee's recommendations were finalized after passage of the
Revitalization Act but before publication of the NIH
Guidelines. Much of the Committee's recommendations
were incorporated to varying degrees into NIH policy;
however, the NIH Guidelines do not specifically address
special rules for pregnant women.
The Committee recognized the potential benefits of
participation in research, such as access to new therapeutic interventions that might otherwise not be available. They emphasized respect for the autonomy of
women to make decisions regarding their participation in
clinical research studies and recommended that women
who participate in research studies should be permitted
to select voluntarily the contraceptive method of their
choice where there are no relevant study-dependent, scientific reasons for excluding certain contraceptives, such
as drug interaction .19 The Committee recommended that
federal policy should assure that neither women nor men
of reproductive age should be excluded from participation in clinical studies.2o Both should have the opportunity to participate in the benefits and burdens of research.
The potential or prospect of becoming pregnant during a
study should not be used as a justification for precluding
or limiting the participation of women of reproductive
age.21 The Committee further recommended that pregnant women should also be presumed eligible for participation in clinical studies.22 At the same time, it is important to note that presuming pregnant women to be eligible is not the equivalent of advocating their active recruitment into every clinical study, as there may be scientifically and medically valid reasons for excluding pregnant
women from a particular study.23
In moving from a paradigm of exclusion to one of
inclusion, much sti)l needs to be done to overcome some
of the barriers that have prevented women from full participation in the past. For this reason ORWH has made
some resources available to assist investigators in their
outreach efforts, by providing support through administrative supplements to ongoing NIH grants. In July of
1993, ORWH sponsored public hearings and a workshop
entitled "Recruitment and Retention of Women in Clinical
Studies," and subsequently published a summary of the
issues and recommendations. 24 The NIH also published
an "Outreach Notebook" that offers some practical suggestions for recruitment and retention of underrepresented subjects.2s

V.

VI.

inclusion plan that must meet the requirement before the
study may commence. 12

IV.

Implementation of the NIH Policy

Women of Childbearing Potential and
Pregnant Women

As a result of government policies on inclusion, the
standard of practice for conducting clinical research is
being changed. It is not entirely clear what effect this will
have on future liability claims by women or their offspring
who are injured as a result of their participation as

In September, 1992, ORWH commissioned the
Institute of Medicine (10M) to establish a Committee on
the Ethical and Legal Issues Relating to the Inclusion of
Women in Clinical Studies (Committee). The Committee
Food, Drug, Cosmetic and Medical Device Law Digest
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women from clinical research.3 9 Indeed, the thalidomide
tragedy, perhaps the most notorious example of injury to
offspring following the use of medication during pregnancy, involved a pharmaceutical that had already been marketed and was in widespread use. Thus, it is arguable
that the failure to include women of childbearing potential
in controlled clinical trials may result in the risk of injury
to more individuals in less controlled and less monitored
circumstances. It is also possible that a medical malpractice claim could result from the inappropriate application of a treatment regimen that was developed
through research in which only men were studied. Thus,
in contrast to a research injury which results from being
included in research, liability for exclusion results from
the lack of data necessary to establish appropriate standards for the treatment of women.
It is also important to note that unforeseen complications and unintended injuries, however tragic they may
be, do not necessarily result in legal liability.
Nevertheless, conscience compels that something be
done to right the wrong. To a certain extent, the scientific
community has already accepted responsibility for some
adverse outcomes related to clinical research. Research
protocols or informed consent documents may provide
that if something goes wrong during the course of a study
the subject will be treated at no expense. However, such
provisions typically do not extend to compensation
beyond immediate medical treatment, nor do they
address injury to offspring. Clearly, more attention must
be given to developing better remedies for potential
injuries associated with research activities. These might
include the possibility of a "no fault" approach for most
research related injuries regardless of liability, while at
the same time preserving the option of tort action for
negligence.

research subjects.26 Liability issues are not addressed in
the NIH Guidelines.
Medical researchers and pharmaceutical manufacturers share a fear that if a woman participating in
research becomes pregnant and her fetus is harmed,
they will be held liable.27 This fear is often the reason for
the exclusion of women from clinical trials, despite a very
low reported incidence of research injuries and few
reported legal cases concerning such injuries.2B Fear of
liability has not, however, operated to exclude men from
participating in clinical trials, despite evidence that some
fetal injury may be attributed to exposure of the father to
toxic substances.29 Ironically, fear of liability has never
operated as a rationale for the inclusion of women in clinical research, even though there may be more legal
precedent for liability for exclusion.3o
The informed consent process is critical to assessing
liability in research.31 Potential liability for injuries to
women and men who participate in clinical research is
unlikely, provided that informed consent to participate in
the research is obtained in accordance with federal regulations and state tort law.32 Liability, then, turns on the
"informed" nature of the woman's consent to participate
in the research and whether she has been adequately
warned about potential risks.331f the researcher has met
the requisite standard of care by warning the woman of
the potential risks of the trial in which she wishes to participate, and she chooses to participate, it is unlikely that
she will succeed in any subsequent negligence action for
injuries that may occur as a result of her participation in
the trial.
Questions of liability more often focus on potential
harm to the future offspring of women who participate in
clinical trials. It is unclear in this context whether obtaining the informed consent of the mother would be sufficient to avoid liability for the injury to the offspring. The
mother's consent would probably suffice when ,the
research is of therapeutic value to the fetus,34 but it is not
clear if this would be the case when the drug or intervention was designed to be therapeutic for the mother
only. 35 To date there has been little case law establishing
parameters for holding researchers or drug manufacturers liable for injuries to the offspring of clinical trial participants, but liability has been found when there was failure to obtain consent.36 It appears, then, that when there
is no negligence and appropriate informed consent to
participation in a clinical trial has been obtained,
researchers and sponsors are unlikely to be held liable in
tort for the inclusion of women in their studies.37
Unlike speculation about liability for inclusion, legal
precedent does exist that has based liability, in part, on
the inadequate testing of a drug before it was released
into the market.38 The evolution of public policy that
establishes the importance of including women in clinical
research has prompted several commentators to suggest
that researchers and drug manufacturers should focus
their concern on liability that results from the exclusion of
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VII. Conclusion
,.

Questions concerning risk of liability are difficult to
resolve, but there is growing consensus that the exclusion of women from research studies may pose just as
much risk of liability as their inclusion. Liability for inclusion depends very much on the informed nature of the
woman's consent to participate in the research. The actual informed consent document should be viewed as more
that just as a piece of paper to protect the sponsor.
Instead, it is an important indicator demonstrating the
quality of interaction that has taken place between investigator and subject throughout the research project.
Perhaps the most cogent argument in favor of the
NIH inclusion policy is the societal cost of continued gaps
in scientific knowledge about important health problems
that affect both women and men of diverse racial-ethnic
groups. 4o Gender differences must be appraised when
generalizing results to entire populations,41 because a
"one size fits all" standard of care is no longer acceptable.42
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